TCM
BBIO icon

Tygh Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Tygh Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$715K Sell
42,848
-86
-0.2% -$3.64K 0.09% 85
2021
Q3 		$2.01M Buy
+42,934
New +$2.3M 0.27% 83

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tygh Capital Management's BBIO Position: Q4 2021 in Review

Tygh Capital Management reduced its BridgeBio Pharma (BBIO) stake by 0.2% in Q4 2021, selling an estimated $3.64K and leaving 42,848 shares worth $715K. The position accounts for 0.09% of the portfolio, ranked #85.

Tygh Capital Management first reported a position in BBIO in Q3 2021 and has held it in 2 quarters since. The position peaked at $2.01M in Q3 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Tygh Capital Management held 42,848 shares of BridgeBio Pharma worth $715K as of Q4 2021.
  • Tygh Capital Management sold 86 BridgeBio Pharma shares in Q4 2021, an estimated $3.64K.
  • BridgeBio Pharma made up 0.09% of Tygh Capital Management's portfolio in Q4 2021, its #85 holding.
  • Tygh Capital Management first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 2 quarters since.
  • Tygh Capital Management's BridgeBio Pharma position peaked at $2.01M in Q3 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.